Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Patterns And Clinical Outcomes Among Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (mBC) Receiving Palbociclib in Combination With Fulvestrant (PB+FUL) In The US Community Oncology Setting

NCT04460911 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04460911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04460911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Patterns And Clinical Outcomes Among Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (mBC) Receiving Palbociclib in Combination With Fulvestrant (PB+FUL) In The US Community Oncology Setting
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
October 19, 2019
Completion date
April 1, 2022
Enrollment
317 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer